Muscle cramps
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Here is a comprehensive overview of muscle cramps drawn from authoritative medical textbooks:
Muscle Cramps
Definition & Characteristics
A muscle cramp is a painful, involuntary, localized muscle contraction with a sudden onset in a single muscle or muscle group. Key features:
- Duration: seconds to minutes
- A palpable, hard, well-defined region of contraction
- Occasional postural distortion
- Fasciculations often precede and follow the cramp
- Relieved by stretching the affected muscle
— Bradley and Daroff's Neurology in Clinical Practice
Pathophysiology
Cramps are thought to originate in motor axons or nerve terminals (not in the muscle itself or the CNS). On EMG, cramp discharges show rapid, repetitive motor unit action potentials at 40–150 per second, rising then falling during the cramp. This electrically active pattern distinguishes true cramps from:
- Contractures (metabolic myopathies) — electrically silent
- Myoedema — also electrically silent
The CNS plays only a minor modulatory role in cramp thresholds.
Who Gets Cramps?
Cramps in the calf/gastrocnemius are extremely common and typically benign and idiopathic. They are more frequent in:
- Elderly individuals (up to 50%)
- At the onset of exercise
- At night (nocturnal cramps)
- During pregnancy
- Patients with fasciculations
- Patients on hemodialysis (~60% of HD sessions)
In up to 60% of patients presenting with cramps, small-fiber neuropathy may be the only underlying disease found after workup.
Causes (Classification)
Ordinary / Benign
- Normal individuals (especially gastrocnemius), older age, pregnancy
Systemic / Metabolic
- Dehydration: sweating, diuretics, hemodialysis
- Electrolyte disturbances: ↓Na⁺, ↓Mg²⁺, ↓Ca²⁺, ↓glucose
- Uremia, cirrhosis, Gitelman syndrome
- Endocrine: hypothyroid or hyperthyroid, hypoadrenal, hyperparathyroid
- Ischemia
Drug-induced
Neurogenic (Partial Denervation)
- Motor neuron disease (e.g., ALS)
- Radiculopathy, spinal stenosis
- Polyneuropathy (including small-fiber neuropathy)
Specific Syndromes
- Cramp-fasciculation syndrome (more disabling cramps + fasciculations, normal EMG except fasciculations)
- Isaacs syndrome (autoimmune, anti-VGKC antibodies; neuropathy + myokymia + neuromyotonia)
- Satoyoshi syndrome
Genetic
- Glycogen storage diseases (McArdle disease — myophosphorylase deficiency; PFK deficiency; phosphoglycerate mutase deficiency)
- Myotonia congenita, myotonic dystrophy
- Brody syndrome (ATP2A1 mutation)
- HANAC syndrome (COL4A1 mutation — hereditary angiopathy with nephropathy, aneurysms, and cramps)
- Becker muscular dystrophy, LGMD 1C
Hemodialysis-Associated Cramps
Occur in ~60% of HD treatments; a common cause of early session termination. Mechanisms:
- Vasoconstriction and impaired O₂ delivery to muscle (especially with hypotension)
- Osmotic and fluid shifts across muscle cells during dialysis
- Accumulation of uremic solutes; nutritional deficiencies
Management: Careful attention to UF rates, reassessing dry weight, increasing dialysis frequency/duration, reducing interdialytic fluid gains. Acute relief: cessation of ultrafiltration ± small normal saline boluses. Vitamin E before bedtime may help. Quinine has been largely abandoned due to serious adverse effects (drug-induced TMA, QT prolongation) and FDA black-box warning.
— Brenner and Rector's The Kidney
Treatment
| Approach | Details |
|---|---|
| Treat underlying cause | Correct metabolic abnormalities (electrolytes, endocrine, etc.) |
| Active stretching | Contract the antagonist muscle (reciprocal inhibition); no clear evidence for prophylactic stretching |
| Mexiletine | Helpful for treating cramps (membrane stabilizer) |
| Quinine sulfate | Effective for nocturnal cramps; side effects may outweigh benefits; FDA black-box warning |
| Carbamazepine, Phenytoin | Anticonvulsant membrane stabilizers |
| Gabapentin | Useful especially in neuropathic etiologies |
| Verapamil | Calcium channel blocker |
| Amitriptyline | Tricyclic antidepressant |
| Tocainide, Mexiletine | Sodium channel blockers |
| Vitamin E, Riboflavin | Supplement options |
| Magnesium lactate/citrate | Especially for pregnancy-related leg cramps |
— Bradley and Daroff's Neurology in Clinical Practice
Key Differential Points
| Feature | Cramp | Contracture | Myotonia |
|---|---|---|---|
| Painful? | Yes | Yes (in metabolic myopathy) | Usually not |
| EMG | Active (40–150 Hz discharges) | Electrically silent | Myotonic runs |
| Relieved by stretch? | Yes | No | No |
| Trigger | Contraction in shortened position | Exercise (ischemic) | Cold, activity |
Summary: Muscle cramps are very common, usually benign, and most often affect the calf. When frequent, involve non-gastrocnemius muscles, or occur alongside weakness or fasciculations, a neurogenic, metabolic, or genetic cause should be sought. Treatment starts with correcting any underlying disorder, with mexiletine and (cautiously) quinine as pharmacologic options.
Intradialytic cramps
Finding Sources
Finding Sources
Reading File
Reading File
Here is a focused, textbook-based review of intradialytic muscle cramps:
Intradialytic Muscle Cramps
Incidence & Impact
- Occur in 5–20% of patients late during dialysis sessions
- Predominantly affect the legs
- Account for approximately 15% of premature dialysis discontinuations
- EMG during cramps shows increased tonic muscle electrical activity throughout dialysis; serum CK may be elevated
— Comprehensive Clinical Nephrology, 7th Edition
Pathophysiology
The exact mechanism remains incompletely understood, but two primary factors are implicated:
- Dialysis-induced volume contraction — excessive ultrafiltration leads to intravascular volume depletion, reducing muscle perfusion
- Hypoosmolality — rapid osmolar shifts during dialysis cause fluid movement into muscle cells
The onset of cramps may signal that the target (dry) weight has been reached or exceeded.
Additional contributing factors:
- Hypomagnesemia
- L-Carnitine deficiency (though evidence is mixed)
- Ultrafiltration rate >13 mL/kg/h (associated with adverse cardiovascular outcomes and cramps)
— Comprehensive Clinical Nephrology, 7th Edition; Harrison's Principles of Internal Medicine 22E
Acute Management
The goal is to rapidly increase plasma osmolality:
| Agent | Dose | Notes |
|---|---|---|
| 23.5% Hypertonic saline | 15–20 mL IV | Risk of postdialytic thirst and ↑ IDWG |
| 50% Dextrose in water | 25–50 mL IV | Preferred (especially in non-diabetics); fewer side effects |
| 25% Mannitol | 50–100 mL IV | Causes transient warmth/flushing; repeated doses → thirst, fluid overload |
All three are equally effective acutely. Cessation of ultrafiltration alone is not useful for cramp relief.
— Comprehensive Clinical Nephrology, 7th Edition
Note: Brenner and Rector's recommends cautious use — hypertonic saline and 50% dextrose can predispose to interdialytic weight gain and hyperglycemia, respectively, so they are less desirable as routine agents.
Prevention
Dialysis prescription adjustments:
- Reduce the ultrafiltration rate — avoid excessive or rapid volume removal
- Ultrafiltration profiling — remove more fluid early in the session, less toward the end
- Sodium modeling (sodium gradient dialysis) — start dialysate Na⁺ at 145–155 mmol/L, then linearly decrease to 135–140 mmol/L by session end. (Exponential, linear, and step programs show similar results)
- Intradialytic blood volume biofeedback — has been shown to reduce cramp incidence
- Reassess dry weight — if no signs of fluid overload, increase dry weight by 0.5 kg and observe
Dietary counseling:
- Reduce dietary sodium intake to limit interdialytic weight gain (IDWG)
Pharmacological prevention (given ~2 hours before dialysis):
| Agent | Dose | Notes |
|---|---|---|
| Quinine sulfate | 250–300 mg orally | Effective in practice; FDA considers unsafe/ineffective for cramps (black-box warning); used widely outside the US |
| Oxazepam | 5–10 mg orally | Benzodiazepine; useful pre-dialysis |
| Vitamin E | Before bedtime | Some supporting data; low risk |
| Enalapril | 5 mg twice weekly | Anecdotal reports; mechanism: inhibits angiotensin II–mediated thirst and vasoconstriction |
| L-Carnitine | 20 mg/kg per dialysis session | Deficiency may contribute; meta-analysis inconclusive |
| Creatine monohydrate | 12 mg before dialysis | Anecdotal benefit |
| Magnesium | Supplementation | Especially if hypomagnesemic |
| Stretching exercises | — | Non-pharmacological adjunct |
Key Clinical Pearls
- Cramps late in dialysis → may indicate the patient is at or below dry weight; consider reassessing target weight
- Cramps with concurrent hypotension → treat both: stop UF + small normal saline bolus
- Low-sodium dialysate increases cramp risk despite other benefits — balance is essential
- Quinine carries FDA black-box warning (risk of thrombotic microangiopathy, QT prolongation, hypersensitivity) — use with caution and informed consent
— Brenner and Rector's The Kidney; Comprehensive Clinical Nephrology, 7th Edition; Harrison's Principles of Internal Medicine 22E
This is a shared conversation. Sign in to Orris to start your own chat.